Understanding how fat tissue affects diabetes remission after weight loss surgery
Improved Adipose Tissue Storage of Dietary Fatty Acids as a New Mechanism for the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery
This study is testing how changes in fat tissue after weight loss surgery can help people with Type 2 Diabetes feel better and possibly go into remission.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Université de Sherbrooke Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Sherbrooke, Quebec) |
| Trial ID | NCT05934409 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the relationship between adipose tissue metabolic changes and the remission of Type 2 Diabetes (T2D) following bariatric surgery. Participants will undergo bariatric surgery and be divided into two groups based on their T2D status. The study involves multiple metabolic sessions before and after surgery, where participants will receive stable tracers, consume a liquid meal, and undergo PET and MRI imaging. The trial aims to determine the role of niacin in regulating lipid metabolism and its impact on glucose production in T2D patients post-surgery.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with a BMI of 35 kg/m2, either diagnosed with Type 2 Diabetes or without.
Not a fit: Patients with uncontrolled medical conditions, overt cardiovascular disease, or contraindications to surgery or MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of Type 2 Diabetes remission after bariatric surgery.
How similar studies have performed: While the approach of linking adipose tissue remodeling to diabetes remission is innovative, similar studies have shown promising results in understanding metabolic changes post-bariatric surgery.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 to 65 * BMI 35 kg/m2 * Diagnosed T2D - according to Diabetes Canada diagnostics criteria. * Diagnosed non-T2D - according to Diabetes Canada diagnostics criteria. * Women with a negative serum pregnancy test. Exclusion Criteria: * Treatment with an oral contraceptive; * Treatment with fibrate, thiazolidinedione, insulin, or beta-blocker, drugs that affect metabolism and cannot be stopped temporarily or which have long-lasting effects; * Presence of overt cardiovascular disease, liver or renal failure or other uncontrolled medical conditions; * Any other contraindication to surgery or to temporarily suspending current medications for diabetes, lipids or hypertension; * Smoking or consumption of more than 2 alcoholic beverages per day; * Any contraindication to MRI; * A Diabetes Remission (DiaRem) score \>8 (low probability of T2D remission); * Having participated to a research study with exposure to radiation in the last two years before the start of the study; * Pregnant or breastfeeding women; * Patients weighing more than 200 kg to respect the weight and gantry limit of our MRI and PET/CT scanners. * Being allergic to eggs
Where this trial is running
Sherbrooke, Quebec
- centre de recherche du CHUS — Sherbrooke, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: André Carpentier, MD — Université de Sherbrooke
- Study coordinator: Frédérique Frisch
- Email: frederique.frisch@usherbrooke.ca
- Phone: 1-819-346-1110
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.